Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 23Lymphoma, Large B-Cell, Diffuse 17Recurrence 7Neoplasms, Plasma Cell 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Hematologic Diseases 2Colorectal Neoplasms 2Blood Protein Disorders 2Sezary Syndrome 1Renal Insufficiency 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 4Dexamethasone 3sargramostim 2Bortezomib 2pomalidomide 1isatuximab 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Thalidomide 1Technetium Tc 99m Pyrophosphate 1Technetium 1Registries 1Radiotherapy 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Ketamine 1Filgrastim 1Carboplatin 1Calcium Dobesilate 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Immunoglobulin Light-chain Amyloidosis × Lenalidomide × Clear all
NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡